Anti-IL-5 therapies for chronic obstructive pulmonary disease-Reference-Cited by-同舟云学术

Anti-IL-5 therapies for chronic obstructive pulmonary disease

Published:2020-12-08 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Donovan Tim¹,Milan Stephen J²,Wang Ran³,Banchoff Emma⁴,Bradley Patrick⁵,Crossingham Iain⁶

Affiliation:

1. Medical and Sport Sciences; University of Cumbria; Lancaster UK

2. Medical School; Lancaster University; Lancaster UK

3. Department of Respiratory Medicine; Manchester University NHS Foundation Trust; Manchester UK

4. PHRI; St George's, University of London; London UK

5. Department of Respiratory Medicine; North West Lung Centre, Wythenshawe Hospital, Manchester University Hospitals NHS Foundation Trust; Manchester UK

6. East Lancashire Hospitals NHS Trust; Blackburn UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference72 articles.

1. A phase 2a study of benralizumab in adults with COPD [Abstract];Brightling;European Respiratory Journal,2014

2. Late-breaking abstract: a phase 2a study of benralizumab in adults with COPD;Brightling;European Respiratory Journal,2014

3. A phase 2a study of benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, in adults with chronic obstructive pulmonary disease and sputum eosinophilia [Abstract];Brightling;American Journal of Respiratory and Critical Care Medicine,2014

4. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study;Brightling;Lancet Respiratory Medicine,2014

5. Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia;Damera;European Respiratory Journal,2015

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular probing using phytoceuticals encapsulated advanced delivery systems in ameliorating lung diseases: Current trends and future prospects;International Immunopharmacology;2024-11

2. Clinical Characteristics and 2-Year Outcomes of Chronic Obstructive Pulmonary Disease Patients With High Blood Eosinophil Counts: A Population-based Prospective Cohort Study in China;Archivos de Bronconeumología;2024-07

3. Elastin-derived peptides favor type 2 innate lymphoid cells in chronic obstructive pulmonary disease;American Journal of Physiology-Lung Cellular and Molecular Physiology;2024-06-01

4. Principaux messages de la deuxième Biennale BPCO 2023 de la SPLF. Le patient au cœur du parcours de soins;Revue des Maladies Respiratoires;2024-05

5. Management of Refractory Chronic Obstructive Pulmonary Disease: A Review;Life;2024-04-24